Hansa Biopharma AB recognizes a write-up of SEK 1.430 billion in intangible assets related to Idefirix in the financial statements of the parent company – no impact on the consolidated financials

LUND, Sweden, July 4, 2023 /PRNewswire/ — Hansa Biopharma AB (publ.) (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, announces today that, in accordance with chapter 4, 6§ of the Swedish Annual Accounts Act (1995:1554) and RFR 2, it has elected…